Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 112

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 112
---
 were made in Canadian dollars. All cash amounts paid to Dr. Paulini, Dr. Guenther, Dr. Gerlach, Dr Teifel and Dr. Ammer
were made in Euros.

  77  

SUMMARY COMPENSATION
TABLE

                                                                             Non-equity incentive plan compensation (1)                                       
  Name and principal position                                                Annual incentive plan                                                            
  Gilles Gagnon,                                      2024      401,610                                                      —            —          401,610  
                                                      2023      414,960                                                      100,400      —          414,960  
                                                      2022      369,008                                                      71,000       —          501,510  
  Giuliano La Fratta                                  2024      168,556                                                      —            —          176,984  
  Stacy Prefontaine, Chief Financial Officer (2)      2024      159,907                                                                              159,907  
                                                      2023      176,377                                                                              176,377  
                                                      2022      151,638                                                                              179,121  
  Gerlach, Matthias                                   2024      129,431                                                      —            8,937      138,367  
  Ammer, Nicola                                       2024      188,392                                                      —            8,937      188,392  
  Teifel, Michael                                     2024      117,777                                                      —            8,937      127,079  
  Reigner, Michel, Chief Technology Officer           2024      213,977                                                      —                       213,977  

(1) Mr. Gagnon, through
Prodev Pharma Inc., earned a bonus of $80,000 for additional services provided.

(2) Ms. Stacy Prefonataine
was succeeded as Chief Financial Officer by Giuliano La Fratta on June 3, 2024.

  78  

Compensation of the Chief Executive Officer

The compensation of our President and Chief Executive
Officer is governed by our executive compensation policy described in the section titled “ Compensation of Executive Officers”,
and the President and Chief Executive Officer participates, together with the other Named Executive Officers, in all our incentive plans.

Mr. Gagnon’s total earnings during the financial
year ended December 31, 2024 was $401,610, including an incentive bonus in the amount of $nil.

For the financial year ended December 31,